Keith A Oberg

This inventor holds 29 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 4 EPO patents, primarily in Drug Formulation Technology. Top assignees: Mannkind Corporation, Medallion Therapeutics, Inc., Monolythix, Inc.. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keith A Oberg. Retrieved from https://idiyas.com/inventor/keith-a-oberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 7)

% Patents Active = 82.8

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 2.9

ph-index = 6

Forward Citations = 256(Granted Patents)

Location History:

Newhall, CA (US) (2020)
Camarillo, CA (US) (2020)
Valencia, CA (US) (2010 - 2021)

Company Filing History:

Medallion Therapeutics, Inc.

Alfred E. Mann Foundation for Scientific Research

patents

5. 1 out of 1,267

Medtronic Minimed, Inc.

patents

6. 1 out of 208

Tandem Diabetes Care, Inc.

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Insulin Infusion Set

Crystalline Microparticle

Fluid Transfer Devices

Drug Affinity

Sample Concentration

Monoliths

Nucleic Acids Detection

Ambulatory Infusion Devices

Valves

Drug Formulation

Active Agents

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12214159 - Insulin infusion set (2025-02-04),

2. 11103459 - Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces (2021-08-31),

3. 11013692 - Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents (2021-05-25),

4. 10858690 - Processing blood samples to detect target nucleic acids (2020-12-08),

5. 10752937 - Processing blood samples to detect target nucleic acids (2020-08-25),

6. 10570439 - Sample concentration devices (2020-02-25),

7. 10357459 - Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents (2019-07-23),

8. 10336881 - Monoliths (2019-07-02),

9. 10143655 - Method of drug formulation (2018-12-04),

10. 10004848 - Valves, valved fluid transfer devices and ambulatory infusion devices including the same (2018-06-26),

11. 9968741 - Valves, valved fluid transfer devices and ambulatory infusion devices including the same (2018-05-15),

12. 9717689 - Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents (2017-08-01),

13. 9468717 - Valves, valved fluid transfer devices and ambulatory infusion devices including the same (2016-10-18),

14. 9464969 - Monoliths (2016-10-11),

15. 9463311 - Valves, valved fluid transfer devices and ambulatory infusion devices including the same (2016-10-11),

Title: Innovations in Drug Formulation by Keith A. Oberg

Introduction

Keith A. Oberg, based in Valencia, CA, is a prominent inventor known for his significant contributions to drug formulation technologies. With a remarkable portfolio of 28 patents, Oberg has developed innovative methods that enhance the efficacy of active agents in pharmaceutical applications.

Latest Patents

Two of his latest patents demonstrate his expertise in this area:

1. **Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces** - This method promotes the adsorption of an active agent to microparticles by modifying the structural properties of the active agent, facilitating favorable association with the microparticle.

2. **Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents** - This method involves coating crystalline microparticles with an active agent by altering the surface properties of the microparticles. This alteration enhances favorable associations of the active agent on the microparticle, modifying electrostatic properties, hydrophobic properties, and hydrogen bonding properties.

Career Highlights

Oberg has made impactful advancements in the field through his roles at notable companies like MannKind Corporation and Medallion Therapeutics, Inc. His work at these organizations has been integral in advancing drug formulation technologies.

Collaborations

Collaboration is essential in scientific innovation, and Oberg has had the privilege of working alongside esteemed colleagues, including Peter Carl Lord and Susan McConnell. Their combined expertise has contributed to the advancements in the methods Oberg has patented.

Conclusion

With a strong track record of innovation in drug formulation, Keith A. Oberg continues to be a valuable contributor to the field. His extensive patent portfolio reflects his dedication to enhancing pharmaceutical technologies, promising better outcomes in drug delivery systems.

Profile summary based on public USPTO records.